Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Mirum Pharmaceuticals, Inc. (MIRM)

Mirum raises 2026 sales guidance to $715 million-$720 million; Q3 posts net loss

Mixed Impact 4 of 5 guidance Written later

Mirum reported third quarter 2026 product sales of $185.7 million, up from $133.0 million a year earlier, and raised its full-year 2026 net product sales guidance to $715 million to $720 million. The company swung to a third-quarter net loss of $40.8 million, or $0.87 per diluted share, from net income of $2.9 million a year earlier, as operating expenses rose to $245.5 million.

Key points

  • Q3 2026 revenue of $185.7 million versus $133.0 million in Q3 2025; LIVMARLI net product sales of $133.4 million, up 45%
  • Q3 2026 net loss of $40.8 million, or $0.87 per diluted share, versus net income of $2.9 million, or $0.05 per diluted share, in Q3 2025
  • Q3 2026 research and development expense of $107.9 million, including $13.5 million of acquired in-process research and development
  • Unrestricted cash, cash equivalents and investments of $500.5 million at September 30, 2026, up from $391.4 million at December 31, 2025

The filing

CompanyMirum Pharmaceuticals, Inc. (MIRM)
Form8-K, current report
Filed with the SECNov 3, 2026, 4:03 PM ET
Accession number0001759425-26-000061

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.